Nicholas Corcoran Sells 3,222 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Nicholas Corcoran sold 3,222 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $129.91, for a total value of $418,570.02. Following the completion of the sale, the insider now owns 21,105 shares in the company, valued at $2,741,750.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

TransMedics Group Price Performance

Shares of TMDX traded down $0.06 during mid-day trading on Wednesday, reaching $127.22. 637,458 shares of the company’s stock were exchanged, compared to its average volume of 769,221. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $132.96. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. The company has a 50-day simple moving average of $87.41 and a two-hundred day simple moving average of $78.57. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -374.35 and a beta of 1.87.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business’s revenue for the quarter was up 132.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) earnings per share. On average, sell-side analysts predict that TransMedics Group, Inc. will post 0.62 EPS for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of TMDX. Venturi Wealth Management LLC acquired a new position in shares of TransMedics Group during the 1st quarter valued at $30,000. Fidelis Capital Partners LLC purchased a new stake in shares of TransMedics Group during the first quarter worth $35,000. Cutler Group LLC CA boosted its position in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares during the last quarter. First Horizon Advisors Inc. grew its stake in TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares in the last quarter. Finally, RiverPark Advisors LLC acquired a new position in TransMedics Group in the 3rd quarter worth about $60,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TMDX shares. Oppenheimer boosted their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Piper Sandler reaffirmed an “overweight” rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a report on Wednesday, May 1st. JPMorgan Chase & Co. boosted their price target on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Finally, Canaccord Genuity Group lifted their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.